Importantly, STC2 is broadly upregulated in human tumours including breast cancer [29–32], colorectal cancer [33], gastric cancer [34], esophageal squamous cell carcinoma (ESCC) [35], prostate cancer [36], renal cell carcinoma (RCC) [37], nasopharyngeal carcinoma [38], head and neck squamous cell carcinoma (HNSCC) [39], hepatocellular carcinoma (HCC) [40], osteosarcoma [41], ovarian cancer [42], lung cancer [43], pancreatic cancer [44], endometrial cancer [45], cervical cancer [46], neuroblastoma [47], gallbladder cancer [48], cholangiocarcinoma [49], and so forth. Here, STC2 is linked to cholangiocarcinoma.